) Schematic diagram of the wild-type GRK6 locus, the GRK6/lox targeting vector, the integrated targeting construct, and the Cre recombinasedeleted GRK6 locus (GRK6-KO). GRK6 exons are shown as open boxes and numbered from the first coding exon (Premont et al., 1999). LoxP sites are shown as filled triangles, and the location of the Southern blot probe as a hatched box. Relevant NheI restriction sites are indicated. (B) Genotyping of targeted GRK6-KO mice. The wild-type and GRK6-KO loci were distinguished by triplex PCR amplification as described in Experimental Procedures. The wt GRK6 locus gives a 460 bp band while the GRK6-KO locus gives a 610 bp band, as indicated. (C) GRK6 protein expression by Western blotting. Membrane proteins from brainstem and striatum (data not shown) of wild-type and GRK6-KO animals were subjected to immunoblotting using an anti-GRK6 antiserum (Stoffel et al., 1994). GRK6-KO homozygote animals exhibit a loss of the 68 kDa immunoreactive band compared to wild-type animals (arrow). The 69 kDa band is a nonspecific interaction, since it is present in GRK5 and GRK4 knockout animals and is not recognized by another GRK6 antiserum (data not shown). (D) GRK6 is present in striatal neurons expressing DARPP-32. Top left:
Immunofluorescence analysis reveals GRK6 immunoreactivity in the striatal neurons of wt mouse (ϩ0.74 from bregma). Top right: Lack of GRK6 immunoreactivity in the striatal neurons of GRK6-KO mouse. Bottom left: DARPP-32 immunoreactivity in the striatal neurons of wt mouse. Bottom right: GRK6 and DARPP-32 are colocalized in the same neuronal population in the striatum of wt mouse. GRK6 immunoreactivity was detected using a commercially available anti-GRK6 antibody (rabbit, 1:50, sc-566, Santa Cruz Biotechnologies, Inc.). Similar observations (data not shown) were made using another anti-GRK6 antiserum (Stoffel et al., 1994) . Note that GRK6 is also expressed in large cholinergic striatal cells, which do not express DARPP-32, but can be labeled with anti-choline acetyltransferase antibody (data not shown). Scale bar is equal to 50 m. marker cassette also flanked by loxP sites ( Figure 1A ). gra as well as dorsal and ventral striatum (ErdtmannVourliotis et al., 2001). The expression level of GRK6 The floxed selection marker genes were removed in vivo by breeding a heterozygote mouse bearing the targeted mRNA in the striatum was found to be higher than that of other GRKs (GRK2, GRK3, and GRK5), suggesting allele with a mouse carrying a CMV-Cre transgene. A pup bearing a deletion of both cassettes, leaving an that GRK6 might be a predominant receptor kinase in this brain area (Erdtmann-Vourliotis et al., 2001). A deinactivated GRK6 gene and no selection marker genes, was identified and used to generate the colony of GRK6 tailed investigation of the expression pattern of GRK6 protein using immunohistochemistry revealed expresknockout (GRK6-KO) mice used here. Deletion of exons 3 through 9 leads to a GRK6 that lacks most of the sion of this kinase in the majority of cells in both dorsal and ventral striatum ( Figure 1D ). Particularly, GRK6 proamino-terminal RGS-like domain as well as half of the conserved catalytic domain elements ( Figure 1A ; Hanks tein was found in the same neuronal population that expresses DARPP-32 (dopamine-and cyclic AMP-reguet al., 1988). Beyond the deletion, exon 10 is out of frame relative to exon 2, so that there is little chance of any lated phosphoprotein, apparent molecular weight of 32,000 Da), a molecule involved in dopaminergic signalactive protein fragments being produced. Animal genotyping was performed using triplex PCR ( Figure 1B) and ing mediated by both D1-like and D2-like dopamine receptors, and a phenotypic marker of the medium-size was confirmed by Southern blotting (data not shown) and by analysis of GRK6 protein levels in membranes spiny GABA neurons of the mammalian striatum ( Figure  1D ; Greengard, 2001). These neurons represent a major prepared from brainstem ( Figure 1C) Figures  2A and 2B) , suggesting that even minor changes in GRK6 levels or activity may result in significant behavioral alterations. The degree of activation induced by cocaine (20 mg/kg, i.p.) in both heterozygous and knockout mice was substantially higher, not only relative to littermate wild-type mice, but also relative to mice of both parental strains (C57BL/6J and 129/SvJ) used to generate the mutants (data not shown).
Repeated administration of cocaine is known to result in a progressive enhancement of psychomotor responses. This phenomenon, termed "behavioral sensitization" or "reverse tolerance," is believed to relate to neuronal adaptations associated with drug addiction ( degree (6-fold) in both GRK6-KO and wild-type mice Similarly to cocaine, amphetamine-induced locomotor (data not shown). Thus, an enhanced locomotor reactivation was significantly enhanced in both GRK6 hetsponse of GRK6 mutants to ␤-phenylethylamine, as well erozygous and "null" mice ( Figure 3A) . as cocaine and amphetamine, is consistent with an enFurthermore, enhanced locomotor responses were hanced responsiveness to dopaminergic activation. observed in both heterozygous and homozygous GRK6 mutant mice when the endogenous "trace amine"
Neurochemical Characterization of Dopamine ␤-phenylethylamine ( mice. In addition, the widespread expression of GRK6 in Importantly, mice lacking another member of this kibrain suggests that nondopaminergic receptor types nase family, GRK5, do not demonstrate such dopaminmay also be physiological targets for this kinase; deergic supersensitivity, but do display exaggeration of tailed investigation will be required to establish the portcentral muscarinic cholinergic responses (Gainetdinov folio of receptors affected in GRK6 mutant mice. It has been previously reported that supersensitivity et al., 1999). Another GRK widely expressed in the brain, amphetamine, and ␤-phenylethylamine on locomotor behavior, mice 7.4), 120 mM NaCl, and 1 mM EDTA, and centrifuged for 20 min at 40,000 ϫ g at 4ЊC. Pellets were resuspended in the same buffer and were placed in activity monitor, 30-60 min later they were injected with drugs or vehicle i.p., and locomotor activity was monitored for incubated for 15 min at 37ЊC to facilitate the removal of endogenous DA. After incubation, membranes were centrifuged for 10 min at the following 90 min. In cocaine sensitization (Wang et 
